Physician profile
David A Sato
NPI 1730272469
$2,416.36
in general payments reported to CMS, 2019-2025
27 companies · $270 in 2025
The $270 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,374 · 2020: $621 · 2021: $26.74 · 2022: $16.34 · 2024: $108 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $274.46 | 2020-2025 | Farapulse |
| Novartis Pharmaceuticals Corporation | $266.29 | 2019-2020 | |
| Amgen INC. | $241.90 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $217.05 | 2019-2021 | |
| Akcea Therapeutics, INC. | $209.29 | 2020 | |
| Medtronic, INC. | $125.89 | 2025 | Symplicity G3 |
| Amarin Pharma, INC. | $114.21 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $106.53 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $105.60 | 2019-2021 | |
| Edwards Lifesciences Corporation | $82.31 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $80.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.13 | 2019 | |
| Abbott Laboratories | $66.91 | 2020-2024 | Aveir, Mitraclip |
| Irhythm Technologies, INC. | $60.75 | 2019-2024 | Zio Monitor, Zio Xt Patch |
| Pfizer INC. | $60.45 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braemar Manufacturing, LLC | $55.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $40.68 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $36.44 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $35.81 | 2019 | |
| Medtronic Vascular, INC. | $26.81 | 2019-2020 | |
| Baxter Healthcare | $25.00 | 2019 | |
| Merck Sharp & Dohme LLC | $23.66 | 2024 | Keytruda |
| Alnylam Pharmaceuticals INC. | $22.10 | 2019 | |
| Mallinckrodt Enterprises LLC | $20.53 | 2019 | |
| Philips North America LLC | $16.34 | 2022 | |
| Getinge USA Sales, LLC | $12.18 | 2019 | |
| Biomerieux INC | $10.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sato listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.